Mordecai Ventures

Coherence Neuro designs therapeutic neurotechnology that manages cancer from within the body through its flagship product, SOMA, a brain-computer interface that provides continuous monitoring and targeted bioelectronic therapy.

Early-stage, often first investor and pre-seed backer writing six-figure checks, a hyper-prolific super-angel studio (~900–1,000 global deals) that incubates ventures via a Paris engineering team and prioritizes founder relationships.

Pre-seed lead investor for deeply technical AI, biotech, climatetech and infrastructure startups, offering female operator-led go-to-market expertise and structured fellowships to source technical-founder deal flow. Divergent Capital is run by two female operator-investors who combine deep-tech investing experience with hands-on go-to-market expertise, and they cultivate deal flow through structured fellowships targeting students and emerging investors in their technical-founder network.

A $78M seed fund run by three Latin American immigrant partners who lead or co-lead rounds by writing $500K-$2.5M checks and taking at least 50% of each funding round. The fund deliberately hunts for breakout startups in overlooked U.S. markets like Seattle, Salt Lake City, and Miami.

Operator Partners is a self-funded $40M-$70M venture fund run entirely on the partners own money without outside investors, led by founders with billion-dollar exits including Flatiron Health (acquired by Roche) and the first investor in fintech unicorn Plaid. They deliberately avoid leading rounds or taking board seats, instead writing $250K-$1M checks alongside lead investors while offering on-demand operator support to founders.

Pre-seed, first institutional investor (including pre-incorporation) focused on overlooked emerging markets (Pakistan, Venezuela, Nigeria, Brazil), offering hyper-operator growth and performance-marketing and hands-on go-to-market experimentation for fintech and marketplaces.